Lewis K, Peris K, Sekulic A, Stratigos A, Dunn L, Eroglu Z, Chang AL, Migden M, Li S, Yoo S-Y, Mohan K, Coates E, Okoye E, Baurain J-F, Bechter O, Hauschild A, Butler M, Hernandez-Aya L, Licitra L, Neves R, Ruiz E, Seebach F, Lowy I, Bowler T, Fury M. Interim Analysis of Phase 2 Results for Cemiplimab in Patients with Metastatic Basal Cell Carcinoma (mBCC) who Progressed on or are Intolerant to Hedgehog Inhibitors (HHIs). J of Skin [Internet]. 2021 Jan. 1 [cited 2024 Jul. 4];5(1):s3. Available from: https://jofskin.org/33014/index.php/skin/article/view/1155